| |  Online-Ressource |
|---|
| Verfasst von: | Levy, Elliot B. [VerfasserIn]  |
|---|
| | Fiel, Maria I. [VerfasserIn] |
|---|
| | Hamilton, Stanley R. [VerfasserIn] |
|---|
| | Kleiner, David E. [VerfasserIn] |
|---|
| | McCall, Shannon J. [VerfasserIn] |
|---|
| | Schirmacher, Peter [VerfasserIn] |
|---|
| | Travis, William [VerfasserIn] |
|---|
| | Kuo, Michael D. [VerfasserIn] |
|---|
| | Suh, Robert D. [VerfasserIn] |
|---|
| | Tam, Alda L. [VerfasserIn] |
|---|
| | Islam, Shaheen U. [VerfasserIn] |
|---|
| | Ferry-Galow, Katherine [VerfasserIn] |
|---|
| | Enos, Rebecca A. [VerfasserIn] |
|---|
| | Doroshow, James H. [VerfasserIn] |
|---|
| | Makhlouf, Hala R. [VerfasserIn] |
|---|
| Titel: | State of the art |
|---|
| Titelzusatz: | toward improving outcomes of lung and liver tumor biopsies in clinical trials; a multidisciplinary approach |
|---|
| Verf.angabe: | Elliot B. Levy, MD; Maria I. Fiel, MD; Stanley R. Hamilton, MD; David E. Kleiner, MD, PhD; Shannon J. McCall, MD; Peter Schirmacher, MD; William Travis, MD; Michael D. Kuo, MD; Robert D. Suh, MD; Alda L. Tam, MD; Shaheen U. Islam, MD, MPH; Katherine Ferry-Galow, PhD; Rebecca A. Enos, MPH; James H. Doroshow, MD; and Hala R. Makhlouf, MD, PhD |
|---|
| E-Jahr: | 2020 |
|---|
| Jahr: | March 5, 2020 |
|---|
| Umfang: | 9 S. |
|---|
| Teil: | volume:38 |
|---|
| | year:2020 |
|---|
| | number:14 |
|---|
| | pages:1633-1640 |
|---|
| | extent:9 |
|---|
| Fussnoten: | Gesehen am 06.04.2021 |
|---|
| Titel Quelle: | Enthalten in: Journal of clinical oncology |
|---|
| Ort Quelle: | Alexandria, Va. : American Society of Clinical Oncology, 1983 |
|---|
| Jahr Quelle: | 2020 |
|---|
| Band/Heft Quelle: | 38(2020), 14, Seite 1633-1640 |
|---|
| ISSN Quelle: | 1527-7755 |
|---|
| Abstract: | PURPOSENational Cancer Institute (NCI)-sponsored clinical trial network studies frequently require biopsy specimens for pharmacodynamic and molecular biomarker analyses, including paired pre- and post-treatment samples. The purpose of this meeting of NCI-sponsored investigators was to identify local institutional standard procedures found to ensure quantitative and qualitative specimen adequacy.METHODSNCI convened a conference on best biopsy practices, focusing on the clinical research community. Topics discussed were (1) criteria for specimen adequacy in the personalized medicine era, (2) team-based approaches to ensure specimen adequacy and quality control, and (3) risk considerations relevant to academic and community practitioners and their patients.RESULTS AND RECOMMENDATIONSKey recommendations from the convened consensus panel included (1) establishment of infrastructure for multidisciplinary biopsy teams with a formalized information capture process, (2) maintenance of standard operating procedures with regular team review, (3) optimization of tissue collection and yield methodology, (4) incorporation of needle aspiration and other newer techniques, and (5) commitment of stakeholders to use of guideline documents to increase awareness of best biopsy practices, with the goal of universally improving tumor biopsy practices. |
|---|
| DOI: | doi:10.1200/JCO.19.02322 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1200/JCO.19.02322 |
|---|
| | Volltext: https://ascopubs.org/doi/10.1200/JCO.19.02322 |
|---|
| | DOI: https://doi.org/10.1200/JCO.19.02322 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1753165350 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
State of the art / Levy, Elliot B. [VerfasserIn]; March 5, 2020 (Online-Ressource)
